Davion Healthcare PLC - (DAVI) closed at $4.07 on October 26, 2026, down 32.2% from the previous close, on volume of 141,075 shares (30-day average 518,944).
Data as of October 26, 2026.
Market Chameleon (Mon, 26-Oct 7:01 AM ET)
Davion Healthcare acquires Humaskan Medical Technology intellectual property for $25M
Seeking Alpha News (Mon, 26-Oct 7:51 AM ET)
Market Chameleon (Mon, 26-Oct 3:50 AM ET)
Davion Healthcare Announces US$25 Million Acquisition of Humaskan Medical Technology IP
Globe Newswire (Mon, 26-Oct 7:30 AM ET)
Davion Healthcare PLC is focus on developing its range of home tests for a range of home test products, to identify potential medical conditions and provide early warning to enable further clinical examination where applicable. It designs, develops, and patents medical products and non-diagnostic devices and then licenses the manufacturing, marketing, sales, and distribution rights for its products to regional or world-wide commercial partners. The company has been operating as a single segment. Its products are BreastCheck, FootFlow, and Testic.
Davion Healthcare PLC - trades on the NASDAQ stock market under the symbol DAVI.
As of October 27, 2026, DAVI stock price declined to $3.74 with 9,242 million shares trading.
DAVI has a market cap of $93.50 million. This is considered a Micro Cap stock.
DAVI support price is $2.51 and resistance is $5.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DAVI shares will trade within this expected range on the day.
